Last 12 months
Inside the activity.
2 purchase rows · 116 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 15 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 29 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 31 |
| Apr 2026 | 0 | 9 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 11 |
| Jul 2026 | 2 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2018 Filed Feb 16, 2018 23:00 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 1,400 | $48.76 | $68,264.00 |
DisclosureSEC source: 0000874015-18-000041 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.31 to $49.02, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 23:00 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 1,400 | $35.53 | $49,742.00 |
DisclosureSEC source: 0000874015-18-000041 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| February 03, 2018 Filed Feb 6, 2018 02:06 UTC Amendment |
LOSCALZO JOSEPHDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 937 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000039 · edgar.xml · derivative · entry 2 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis commn stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis ommon stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis ommon stock or cash as may be determined by the Company. Read SEC document |
| February 03, 2018 Filed Feb 6, 2018 02:06 UTC Amendment |
LOSCALZO JOSEPHDirector
|
Exercise / conversionCommon Stock | 937 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000039 · edgar.xml · nonDerivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on February 3, 2014. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on February 3, 2014. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 00:58 UTC Amendment |
BENNETT C FRANKSVP, Antisense Research
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-18-000037 · edgar.xml · derivative · entry 3 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,513 Underlying: Common Stock · 12,500 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 00:58 UTC Amendment |
BENNETT C FRANKSVP, Antisense Research
|
SaleCommon Stock | 12,500 | $52.50 | $656,260.00 |
DisclosureSEC source: 0000874015-18-000037 · edgar.xml · nonDerivative · entry 2 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,114 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.32 to $52.68, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 00:58 UTC Amendment |
BENNETT C FRANKSVP, Antisense Research
|
Exercise / conversionCommon Stock | 12,500 | $7.25 | $90,625.00 |
DisclosureSEC source: 0000874015-18-000037 · edgar.xml · nonDerivative · entry 1 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. Read SEC document |
| January 30, 2018 Filed Jan 31, 2018 21:18 UTC Amendment |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $35.53 | $0.00 |
DisclosureSEC source: 0000874015-18-000035 · edgar.xml · derivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 3,000 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2018 Filed Jan 31, 2018 21:18 UTC Amendment |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 3,000 | $52.86 | $158,580.00 |
DisclosureSEC source: 0000874015-18-000035 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.75 to $53.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| January 30, 2018 Filed Jan 31, 2018 21:18 UTC Amendment |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 3,000 | $35.53 | $106,590.00 |
DisclosureSEC source: 0000874015-18-000035 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 21:16 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 300 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000874015-18-000034 · edgar.xml · derivative · entry 6 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common Stock · 300 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 21:16 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 55 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000874015-18-000034 · edgar.xml · derivative · entry 5 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 21:16 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
SaleCommon Stock | 300 | $55.00 | $16,500.00 |
DisclosureSEC source: 0000874015-18-000034 · edgar.xml · nonDerivative · entry 4 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,452 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 21:16 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
Exercise / conversionCommon Stock | 300 | $10.82 | $3,246.00 |
DisclosureSEC source: 0000874015-18-000034 · edgar.xml · nonDerivative · entry 3 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 21:16 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
SaleCommon Stock | 55 | $55.00 | $3,025.00 |
DisclosureSEC source: 0000874015-18-000034 · edgar.xml · nonDerivative · entry 2 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,452 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 21:16 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
Exercise / conversionCommon Stock | 55 | $10.82 | $595.10 |
DisclosureSEC source: 0000874015-18-000034 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 21:15 UTC Amendment |
CROOKE STANLEY TDirector · Chairman and CEO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000874015-18-000033 · edgar.xml · derivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 6,904 Underlying: Common Stock · 1,000 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 21:15 UTC Amendment |
CROOKE STANLEY TDirector · Chairman and CEO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $14.69 | $0.00 |
DisclosureSEC source: 0000874015-18-000033 · edgar.xml · derivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,642 Underlying: Common Stock · 10,000 shares Expires 2020-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 21:15 UTC Amendment |
CROOKE STANLEY TDirector · Chairman and CEO
|
SaleCommon Stock | 1,000 | $54.12 | $54,120.00 |
DisclosureSEC source: 0000874015-18-000033 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 4,128 F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 21:15 UTC Amendment |
CROOKE STANLEY TDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 1,000 | $10.82 | $10,820.00 |
DisclosureSEC source: 0000874015-18-000033 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 5,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 21:15 UTC Amendment |
CROOKE STANLEY TDirector · Chairman and CEO
|
SaleCommon Stock | 10,000 | $54.12 | $541,200.00 |
DisclosureSEC source: 0000874015-18-000033 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,733 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/20/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/20/2016. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 21:15 UTC Amendment |
CROOKE STANLEY TDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 10,000 | $14.69 | $146,900.00 |
DisclosureSEC source: 0000874015-18-000033 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/20/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/20/2016. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 21:08 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 645 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000874015-18-000029 · edgar.xml · derivative · entry 3 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55 Underlying: Common Stock · 645 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 21:08 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
SaleCommon Stock | 645 | $55.00 | $35,475.00 |
DisclosureSEC source: 0000874015-18-000029 · edgar.xml · nonDerivative · entry 2 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,452 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 21:08 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
Exercise / conversionCommon Stock | 645 | $10.82 | $6,978.90 |
DisclosureSEC source: 0000874015-18-000029 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 02:46 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
SaleCommon Stock | 2,724 | $51.76 | $140,994.24 |
DisclosureSEC source: 0000874015-18-000027 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.760 to $51.763, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 02:28 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $35.53 | $0.00 |
DisclosureSEC source: 0000874015-18-000024 · edgar.xml · derivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 3,000 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 02:28 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 1,400 | $52.97 | $74,158.00 |
DisclosureSEC source: 0000874015-18-000024 · edgar.xml · nonDerivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.80 to $53.15, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 02:28 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 1,400 | $35.53 | $49,742.00 |
DisclosureSEC source: 0000874015-18-000024 · edgar.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 02:28 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 1,600 | $52.13 | $83,408.00 |
DisclosureSEC source: 0000874015-18-000024 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.77 to $52.581, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 02:28 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 1,600 | $35.53 | $56,848.00 |
DisclosureSEC source: 0000874015-18-000024 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 02:26 UTC |
Geary Richard SSVP, Development
|
SaleCommon Stock | 2,723 | $51.76 | $140,942.48 |
DisclosureSEC source: 0000874015-18-000023 · edgar.xml · nonDerivative · entry 2 Geary Richard S · CIK 0001442730 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,680 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.760 to $51.762, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full inormation regading the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 02:25 UTC |
PARSHALL B LYNNEDirector
|
SaleCommon Stock | 5,986 | $51.76 | $309,835.36 |
DisclosureSEC source: 0000874015-18-000022 · edgar.xml · nonDerivative · entry 2 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,180 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.760 to $51.761, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 02:23 UTC |
Boyce SarahChief Business Officer
|
SaleCommon Stock | 2,196 | $51.76 | $113,664.96 |
DisclosureSEC source: 0000874015-18-000020 · edgar.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,931 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 02:25 UTC |
O'NEIL PATRICK R.SVP, Legal & General Counsel
|
SaleCommon Stock | 2,697 | $51.76 | $139,596.72 |
DisclosureSEC source: 0000874015-18-000021 · edgar.xml · nonDerivative · entry 2 O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,452 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.759 to $51.761, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 02:22 UTC |
BENNETT C FRANKSVP, Antisense Research
|
SaleCommon Stock | 2,696 | $51.76 | $139,544.96 |
DisclosureSEC source: 0000874015-18-000019 · edgar.xml · nonDerivative · entry 2 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,114 F3 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.760 to $51.761, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 02:21 UTC | SaleCommon Stock | 2,821 | $51.76 | $146,014.96 |
DisclosureSEC source: 0000874015-18-000017 · edgar.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,783 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.759 to $51.761, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
|
| January 15, 2018 Filed Jan 18, 2018 02:46 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
Exercise / conversionRestricted Stock Units · Derivative | 6,732 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000027 · edgar.xml · derivative · entry 4 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,217 Underlying: Common Stock · 6,732 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:46 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
GrantRestricted Stock Units · Derivative | 12,137 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000027 · edgar.xml · derivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,137 Underlying: Common Stock · 12,137 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:46 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
Exercise / conversionCommon Stock | 6,732 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000027 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:26 UTC |
Geary Richard SSVP, Development
|
Exercise / conversionRestricted Stock Units · Derivative | 6,732 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000023 · edgar.xml · derivative · entry 4 Geary Richard S · CIK 0001442730 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,217 Underlying: Common Stock · 6,732 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:26 UTC |
Geary Richard SSVP, Development
|
GrantRestricted Stock Units · Derivative | 12,916 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000023 · edgar.xml · derivative · entry 3 Geary Richard S · CIK 0001442730 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,916 Underlying: Common Stock · 12,916 shares Expires not disclosed F4 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:26 UTC |
Geary Richard SSVP, Development
|
Exercise / conversionCommon Stock | 6,732 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000023 · edgar.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:25 UTC |
PARSHALL B LYNNEDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 18,339 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000022 · edgar.xml · derivative · entry 4 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,185 Underlying: Common Stock · 18,339 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:25 UTC |
PARSHALL B LYNNEDirector
|
GrantRestricted Stock Units · Derivative | 23,016 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000022 · edgar.xml · derivative · entry 3 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,016 Underlying: Common Stock · 23,016 shares Expires not disclosed F4 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:25 UTC |
PARSHALL B LYNNEDirector
|
Exercise / conversionCommon Stock | 18,339 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000022 · edgar.xml · nonDerivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:23 UTC |
Boyce SarahChief Business Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 5,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000020 · edgar.xml · derivative · entry 4 Boyce Sarah · CIK 0001629383 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,427 Underlying: Common Stock · 5,367 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F4 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:23 UTC |
Boyce SarahChief Business Officer
|
GrantRestricted Stock Units · Derivative | 12,916 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000020 · edgar.xml · derivative · entry 3 Boyce Sarah · CIK 0001629383 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,916 Underlying: Common Stock · 12,916 shares Expires not disclosed F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F4 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:23 UTC |
Boyce SarahChief Business Officer
|
Exercise / conversionCommon Stock | 5,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000020 · edgar.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:25 UTC |
O'NEIL PATRICK R.SVP, Legal & General Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 6,663 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000021 · edgar.xml · derivative · entry 4 O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,148 Underlying: Common Stock · 6,663 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.